Roche ends Huntington’s gene-silencing programs after disappointing data

Roche has abandoned two Huntington’s gene-silencing drugs after disappointing data, according to STAT+. The report does not provide additional details on the programs or the specific results that led to the decision. The item appears in a biotech roundup that also mentions ARPA-H’s new $160 million effort to accelerate bespoke gene-editing therapies for rare diseases into the clinic. It further notes that drugmakers have moved to promote Medicare’s new obesity drug discount program. No further information on the Huntington’s programs, including timing, study findings, or next steps, was reported in the source excerpt.